Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: An update

Schizophrenia Bulletin

Volumn 40, Issue 1, 2014, Pages 181-191

  Sommer, Iris E ^a   Van Westrhenen, Roos ^a   Begemann, Marieke J H ^a   De Witte, Lot D ^a   Leucht, Stefan ^b   Kahn, René S ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

add on antipsychotic therapy; aspirin; estrogens; N acetylcysteine

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; CELECOXIB; DAVUNETIDE; DOCOSAHEXAENOIC ACID; ESTROGEN; ICOSAPENTAENOIC ACID; MINOCYCLINE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; COGNITION; DRUG EFFICACY; EFFECT SIZE; HUMAN; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; SYMPTOM; SYSTEMATIC REVIEW;

ADD-ON ANTIPSYCHOTIC THERAPY; ASPIRIN; ESTROGENS; N-ACETYLCYSTEINE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; SCHIZOPHRENIA;

EID: 84892647238     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbt139     Document Type: Article

References (95)

1. Torrey EF, Peterson MR. Slow and latent viruses in schizophrenia. Lancet. 1973;2:22-24.
2. Fineberg AM, Ellman LM. Inflammatory cytokines and neurological and neurocognitive alterations in the course of schizophrenia. Biol Psychiatry. 2013;73:951-966.
3. Monji A, Kato T, Kanba S. Cytokines and schizophrenia: microglia hypothesis of schizophrenia. Psychiatry Clin Neurosci. 2009;63:257-265.
4. Drexhage RC, Weigelt K, van Beveren N, et al Immune and neuroimmune alterations in mood disorders and schizophrenia. Int Rev Neurobiol. 2011;101:169-201.
5. Chew LJ, Fusar-Poli P, Schmitz T. Oligodendroglial alterations and the role of microglia in white matter injury: relevance to schizophrenia. Dev Neurosci. 2013;27:1-28.
6. Muller N, Schwarz M. Schizophrenia as an inflammationmediated dysbalance of glutamatergic neurotransmission. Neurotox Res. 2006;10:131-148.
7. M?ler N, Dursun SM. Schizophrenia genes, epigenetics and psychoneuroimmunology therapeutics: all make sense now? J Psychopharmacol. 2011;25:713-714.
8. de Jong S, van Eijk KR, Zeegers DW, et al; PGC Schizophrenia (GWAS) Consortium. Expression QTL analysis of top loci from GWAS meta-analysis highlights additional schizophrenia candidate genes. Eur J Hum Genet. 2012;20:1004-1008.
9. Dickerson F, Stallings C, Origoni A, Boronow J, Yolken R. C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophr Res. 2007;93:261-265.
10. Dickerson F, Stallings C, Origoni A, et al C-reactive protein is elevated in schizophrenia. Schizophr Res. 2013;143:198-202.
11. Dickerson F, Stallings C, Origoni A, Vaughan C, Khushalani S, Yolken R. Elevated C-reactive protein and cognitive deficits in individuals with bipolar disorder. J Affect Disord. 2013;150:456-459.
12. Lavisse S, Guillermier M, H?ard AS, et al Reactive astrocytes overexpress TSPO and are detected by TSPO positron emission tomography imaging. J Neurosci. 2012;32:10809-10818.
13. Cosenza-Nashat M, Zhao ML, Suh HS, et al Expression of the translocator protein of 18 kDa by microglia, macrophages and astrocytes based on immunohistochemical localization in abnormal human brain. Neuropathol Appl Neurobiol. 2009;35:306-328.
14. van Berckel BN, Bossong MG, Boellaard R, et al Microglia activation in recent-onset schizophrenia: a quantitative ?-[11C]PK11195 positron emission tomography study. Biol Psychiatry. 2008;64:820-822.
15. Doorduin J, de Vries EF, Willemsen AT, de Groot JC, Dierckx RA, Klein HC. Neuroinflammation in schizophrenia-related psychosis: a PET study. J Nucl Med. 2009;50:1801-1807.
16. Takano A. The application of PET technique for the development and evaluation of novel antipsychotics. Curr Pharm Des. 2010;16:371-377.
17. Benros ME, Nielsen PR, Nordentoft M, Eaton WW, Dalton SO, Mortensen PB. Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year populationbased register study. Am J Psychiatry. 2011;168:1303-1310.
18. Benros ME, Mortensen PB, Eaton WW. Autoimmune diseases and infections as risk factors for schizophrenia. Ann N Y Acad Sci. 2012;1262:56-66.
19. Eaton WW, Byrne M, Ewald H, et al Association of schizophrenia and autoimmune diseases: linkage of Danish national registers. Am J Psychiatry. 2006;163:521-528.
20. Sommer IE, de Witte L, Begemann M, Kahn RS. Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis. J Clin Psychiatry. 2012;73:414-419.
21. Dodd S, Maes M, Anderson G, Dean OM, Moylan S, Berk M. Putative neuroprotective agents in neuropsychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2013;42:135-145.
22. Pettit LK, Varsanyi C, Tadros J, Vassiliou E. Modulating the inflammatory properties of activated microglia with docosahexaenoic acid and aspirin. Lipids Health Dis. 2013;12:16.
23. Chan ES, Cronstein BN. Methotrexate-how does it really work? Nat Rev Rheumatol. 2010;6:175-178.
24. Watabe M, Kato TA, Monji A, Horikawa H, Kanba S. Does minocycline, an antibiotic with inhibitory effects on microglial activation, sharpen a sense of trust in social interaction? Psychopharmacology (Berl). 2012;220:551-557.
25. Liu X, Fan X, Zhao Y, et al Estrogen provides neuroprotection against activated microglia-induced dopaminergic neuronal injury through both estrogen receptor-? and estrogen receptor-? in microglia. J Neurosc Res. 2005;81:653-665.
26. Tynan RJ, Weidenhofer J, Hinwood M, Cairns MJ, Day TA, Walker FR. A comparative examination of the antiinflammatory effects of SSRI and SNRI antidepressants on LPS stimulated microglia. Brain Behav Immun. 2012;26:469-479.
27. Hu X, Zhou H, Zhang D, et al Clozapine protects dopaminergic neurons from inflammation-induced damage by inhibiting microglial overactivation. J Neuroimmune Pharmacol. 2012;7:187-201.
28. Albayrak A, Halici Z, Polat B, et al Protective effects of lithium: a new look at an old drug with potential antioxidative and anti-inflammatory effects in an animal model of sepsis. Int Immunopharmacol. 2013;16:35-40.
29. Ximenes JC, de Oliveira Gon?lves D, Siqueira RM, et al Valproic acid: an anticonvulsant drug with potent antinociceptive and anti-inflammatory properties. Naunyn Schmiedebergs Arch Pharmacol. 2013;386:575-587.
30. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred Reporting Items for Systematic reviews and Meta-Analyses: the PRISMA statement. J Clin Epidemiol. 2009;62:1006-1012.
31. Lipsey MW, Wilson DB. Practical Meta-Analysis. Thousand Oaks, CA: Sage; 2001.
32. Lipsey MW, Wilson DB. The way in which intervention studies have "personality" and why it is important to meta-analysis. Eval Health Prof. 2001;24:236-254.
33. Newcomer JW, Craft S, Askins K, et al Glucocorticoid interactions with memory function in schizophrenia. Psychoneuroendocrinology. 1998;23:65-72.
34. Rosenthal R. Meta-Analytic Procedures for Social Research. London, UK: Sage; 1991.
35. Shaddish WR, Haddock CK. Combining estimates of effect size. In: Coopers H, Hedges V, eds. The Handbook of Research Synthesis. New York, NY: Sage Publications; 1994: 226-285, 261-281.
36. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560.
37. Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest. 1975;56:624-632.
38. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol. 1998;38:97-120.
39. Nye EJ, Hockings GI, Grice JE, et al Aspirin inhibits vasopressin-induced hypothalamic-pituitary-adrenal activity in normal humans. J Clin Endocrinol Metab. 1997;82:812-817.
40. Vasovi? V, Bani? B, Jakovljevi? V, Tomic Z, Milic-Djordjevic V. Effect of aminophylline on aspirin penetration into the central nervous system in rats. Eur J Drug Metab Pharmacokinet. 2008;33:23-30.
41. Laan W, Grobbee DE, Selten JP, Heijnen CJ, Kahn RS, Burger H. Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2010;71:520-527.
42. Weiser M, Burshtein S, Fodoreanu L, et al A randomized trial administering aspirin, minocycline or pramipexole vs placebo as add-on to antipsychotics in patients with schizophrenia or schizoaffective disorder [abstract]. Neuropsychopharmacology. 2012;38:S314-S446.
43. Simon LS. Role and regulation of cyclooxygenase-2 during inflammation. Am J Med. 1999;106:37S-42S.
44. Davies NM, McLachlan AJ, Day RO, Williams KM. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet. 2000;38:225-242.
45. M?ler N, Krause D, Dehning S, et al Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr Res. 2010;121:118-124.
46. M?ler N, Riedel M, Scheppach C, et al Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry. 2002;159:1029-1034.
47. Rappard F, Muller N. Celecoxib add-on does not have beneficial antipsychotic effects over risperidone alone in schizophrenia [abstract]. Neuropsychopharmacology. 2004;29:S183-S241.
48. Rapaport MH, Delrahim KK, Bresee CJ, Maddux RE, Ahmadpour O, Dolnak D. Celecoxib augmentation of continuously ill patients with schizophrenia. Biol Psychiatry. 2005;57:1594-1596.
49. Akhondzadeh S, Tabatabaee M, Amini H, Ahmadi Abhari SA, Abbasi SH, Behnam B. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr Res. 2007; 90:179-185.
50. Gozes I, Divinski I. NAP, a neuroprotective drug candidate in clinical trials, stimulates microtubule assembly in the living cell. Curr Alzheimer Res. 2007;4:507-509.
51. Javitt DC, Buchanan RW, Keefe RS, et al Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. Schizophr Res. 2012;136:25-31.
52. Calder PC. Mechanism of action of (n-3)fatty acids. J Nutr. 2012;142:592S-599S.
53. Solfrizzi V, Frisardi V, Capurso C, et al Dietary fatty acids in dementia and predementia syndromes: epidemiological evidence and possible underlying mechanisms. Ageing Res Rev. 2010;9:184-199.
54. Glantz LA, Lewis DA. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch Gen Psychiatry. 2000;57:65-73.
55. Fenton WS, Dickerson F, Boronow J, Hibbeln JR, Knable M. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry. 2001;158:2071-2074.
56. Peet M, Brind J, Ramchand CN, Shah S, Vankar GK. Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr Res. 2001;49:243-251.
57. Emsley R, Myburgh C, Oosthuizen P, van Rensburg SJ. Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am J Psychiatry. 2002;159:1596-1598.
58. Emsley R, Niehaus DJ, Koen L, et al The effects of eicosapentaenoic acid in tardive dyskinesia: a randomized, placebocontrolled trial. Schizophr Res. 2006;84:112-120.
59. Berger GE, Proffitt TM, McConchie M, et al Ethyleicosapentaenoic acid in first-episode psychosis: a randomized, placebo-controlled trial. J Clin Psychiatry. 2007;68:1867-1875.
60. Peet M, Horrobin DF; E-E Multicentre Study Group. A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J Psychiatr Res. 2002;36:7-18.
61. Kulkarni J, Riedel A, de Castella AR, et al Estrogen-a potential treatment for schizophrenia. Schizophr Res. 2001;48:137-144.
62. Akhondzadeh S, Nejatisafa AA, Amini H, et al Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo-controlled trial. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:1007-1012.
63. Louz?MR, Marques AP, Elkis H, Bassitt D, Diegoli M, Gattaz WF. Conjugated estrogens as adjuvant therapy in the treatment of acute schizophrenia: a double-blind study. Schizophr Res. 2004;66:97-100.
64. Kulkarni J, de Castella A, Fitzgerald PB, et al Estrogen in severe mental illness: a potential new treatment approach. Arch Gen Psychiatry. 2008;65:955-960.
65. Kulkarni J, de Castella A, Headey B, et al Estrogens and men with schizophrenia: is there a case for adjunctive therapy? Schizophr Res. 2011;125:278-283.
66. Ghafari E, Fararouie M, Shirazi HG, Farhangfar A, Ghaderi F, Mohammadi A. Combination of estrogen and antipsychotics in the treatment of women with chronic schizophrenia: a double-blind, randomized, placebo-controlled clinical trial. Clin Schizophr Relat Psychoses. 2013;6:172-176.
67. Levkovitz Y, Mendlovich S, Riwkes S, et al A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry. 2010;71:138-149.
68. Chaudhry IB, Hallak J, Husain N, et al Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J Psychopharmacol. 2012;26:1185-1193.
69. Palacio JR, Markert UR, Mart?ez P. Anti-inflammatory properties of N-acetylcysteine on lipopolysaccharide-activated macrophages. Inflamm Res. 2011;60:695-704.
70. Oja SS, Jan?y R, Varga V, Saransaari P. Modulation of glutamate receptor functions by glutathione. Neurochem Int. 2000;37:299-306.
71. Farr SA, Poon HF, Dogrukol-Ak D, et al The antioxidants alpha-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. J Neurochem. 2003;84:1173-1183.
72. Berk M, Copolov D, Dean O, et al N-acetyl cysteine as a glutathione precursor for schizophrenia-a double-blind, randomized, placebo-controlled trial. Biol Psychiatry. 2008;64:361-368.
73. M?ler N, Riedel M, Schwarz MJ, Engel RR. Clinical effects of COX-2 inhibitors on cognition in schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2005;255:149-151.
74. Nitta M, Kishimoto T, M?ler N, Weiser M, et al Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials. Schizophr Bull. May 29, 2013.
75. Rodriguez-Perez AI, Valenzuela R, Villar-Cheda B, Guerra MJ, Labandeira-Garcia JL. Dopaminergic neuroprotection of hormonal replacement therapy in young and aged menopausal rats: role of the brain angiotensin system. Brain. 2012;135:124-138.
76. S?chez MG, Morissette M, Di Paolo T. Effect of a chronic treatment with 17?-estradiol on striatal dopamine neurotransmission and the Akt/GSK3 signaling pathway in the brain of ovariectomized monkeys. Psychoneuroendocrinology. 2012;37:280-291.
77. O'Dell JR, Haire CE, Palmer W, et al Treatment of early rheumatoid arthritis with minocycline or placebo: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 1997;40:842-848.
78. Gordon PH, Moore DH, Miller RG, et al; Western ALS Study Group. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol. 2007;6:1045-1053.
79. Leigh PN, Meininger V, Bensimon G, Cudkowicz M, Robberecht W. Minocycline for patients with ALS. Lancet Neurol. 2008;7:119-120; author reply 120.
80. Manev H, Manev R. Interactions with GluR1 AMPA receptors could influence the therapeutic usefulness of minocycline in ALS. Amyotroph Lateral Scler. 2009;10:416-417.
81. Mannargudi B, McNally D, Reynolds W, Uetrecht J. Bioactivation of minocycline to reactive intermediates by myeloperoxidase, horseradish peroxidase, and hepatic microsomes: implications for minocycline-induced lupus and hepatitis. Drug Metab Dispos. 2009;37:1806-1818.
82. Ramakrishna J, Johnson AR, Banner BF. Long-term minocycline use for acne in healthy adolescents can cause severe autoimmune hepatitis. J Clin Gastroenterol. 2009;43:787-790.
83. Ahmed F, Kelsey PR, Shariff N. Lupus syndrome with neutropenia following minocycline therapy-a case report. Int J Lab Hematol. 2008;30:543-545.
84. Tehrani R, Nash-Goelitz A, Adams E, Dahiya M, Eilers D. Minocycline-induced cutaneous polyarteritis nodosa. J Clin Rheumatol. 2007;13:146-149.
85. Benjamin RW, Calikoglu AS. Hyperthyroidism and lupus-like syndrome in an adolescent treated with minocycline for acne vulgaris. Pediatr Dermatol. 2007;24:246-249.
86. Leydet H, Armingeat T, Pham T, Lafforgue P. [Minocyclineinduced lupus-like disease]. Rev Med Interne. 2006; 27:72-75.
87. van Steensel MA. Why minocycline can cause systemic lupus-a hypothesis and suggestions for therapeutic interventions based on it. Med Hypotheses. 2004;63:31-34.
88. Bachmeyer C, Cadranel JF. Minocycline-induced lupus and autoimmune hepatitis: family autoimmune disorders as possible risk factors. Dermatology. 2002;205:185-186.
89. Schmaal L, Veltman DJ, Nederveen A, van den Brink W, Goudriaan AE. N-acetylcysteine normalizes glutamate levels in cocaine-dependent patients: a randomized crossover magnetic resonance spectroscopy study. Neuropsychopharmacology. 2012;37:2143-2152.
90. Somaini L, Donnini C, Raggi MA, et al Promising medications for cocaine dependence treatment. Recent Pat CNS Drug Discov. 2011;6:146-160.
91. Dean O, Giorlando F, Berk M. N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J Psychiatry Neurosci. 2011;36:78-86.
92. Gray KM, Watson NL, Carpenter MJ, Larowe SD. N-acetylcysteine (NAC) in young marijuana users: an openlabel pilot study. Am J Addict. 2010;19:187-189.
93. LaRowe SD, Myrick H, Hedden S, et al Is cocaine desire reduced by N-acetylcysteine? Am J Psychiatry. 2007;164:1115-1117.
94. Yrj?heikki J, Kein?en R, Pellikka M, H?felt T, Koistinaho J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci USA. 1998;95:15769-15774.
95. Ferreira AP, Pasin JS, Saraiva AL, et al N-acetylcysteine prevents baker's-yeast-induced inflammation and fever. Inflamm Res. 2012;61:103-112.